SEARCH

SEARCH BY CITATION

References

  • 1
    Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1447784.
  • 2
    Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 269: 218338.
  • 3
    Hendriks D, Wang W, Scharpe S, Lommaert MP, Van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 8692.
  • 4
    Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 1593744.
  • 5
    Campbell W, Okada H. Arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 9339.
  • 6
    Nesheim ME, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 38691.
  • 7
    Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093100.
  • 8
    Bajzar L, Morser J, Nesheim ME. TAFI, or plasma carboxypeptidase B couples the coagulation and fibrinolytic cascades through the thrombin–thrombomodulin complex. J Biol Chem 1996; 271: 166038.
  • 9
    Esmon CT, Johnson AE, Esmon NL. Initiation of the protein C pathway. Ann NY Acad Sci 1991; 614: 3043.
  • 10
    Kokame K, Zheng X, Sadler JE. Activation of thrombin-activatable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 1998; 273: 121359.
  • 11
    Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost 1998; 79: 3717.
  • 12
    Mosnier LO, Meijers JCM, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 511.
  • 13
    Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 9: 25348.
  • 14
    Marx PF, Hakeng TM, Dawson PE, Griffin JH, Meijers JCM, Bouma BN. Inactivation of active thrombin-activatable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 124105.
  • 15
    Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 2000; 275: 1286878.
  • 16
    Madison EL. Probing structure–function relationships of tissue-type plasminogen activator by site-specific mutagenesis. Fibrinolysis 1994; 8 (Suppl. 1): 22136.
  • 17
    Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 76308.
  • 18
    Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2717681.
  • 19
    Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 1447782.
  • 20
    Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996; 93: 132830.
  • 21
    Minnema MC, Friederich PW, Levi M, Von Dem Borne PA, Mosnier LO, Meijers JC, Blemond BJ, Hack CE, Bouma, BN, Ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: in vivo evidence for the role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 104.
  • 22
    Robbie LA, Young SP, Bennett B, Booth NA. Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and PAI-1 content and distribution. Thromb Haemost 1997; 77: 5105.
  • 23
    Robbie LA, Booth NA, Croll AM, Bennett B. The roles of α2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 3016.
  • 24
    Urano T, Ihara H, Suzuki Y, Nagai N, Takada Y, Takada A. Soluble thrombomodulin quenches thrombin-mediated neutralization of PAI-1 activity and inhibits fibrinolysis through a TAFI independent mechanism. Fibrinolysis Proteolysis 1999; 13: 26471.
  • 25
    Nagashima M, Werner M, Wang M, Zhao L, Light DR, Paglia R, Morser J, Verhallen P. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor poteniates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 33342.
  • 26
    McWilliam NA, Robbie LA, Barelle CJ, Adey G, Prasad S, Bennett B, Booth NA. Evidence for an active fibrinolytic system in normal human bone marrow. Br J Haematol 1996; 93: 1706.
  • 27
    Mutch NJ, Robbie LA, Booth NA. Human thrombi contain an abundance of thrombin. Thromb Haemost 2001; 86: 102834.
  • 28
    Moir E, Booth NA, Bennett B, Robbie LA. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol 2001; 113: 7280.
  • 29
    Mutch NJ, Moir E, Robbie LA, Berry SH, Bennett B, Booth NA. Localization and identification of thrombin and plasminogen activator activities in model human thrombi by in situ zymography. Thromb Haemost 2002; 88: 9961002.
  • 30
    Robbie LA, Bennett B, Croll AM, Brown PAJ, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 75: 12733.
  • 31
    Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 34869.
  • 32
    Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 143: 7789.
  • 33
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 2001; 85: 6616.
  • 34
    Rijken DC, Sakharov DV. Basic principles in thrombolysis: regulatory role of plasminogen. Thromb Res 2001; 103 (Suppl. 1): S419.
  • 35
    Ellis V, Dano K. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. J Biol Chem 1993; 268: 480613.
  • 36
    Liu JN, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 1992; 31: 63117.
  • 37
    Declerck PJ, Lijnen HR, Verstreken M, Collen D. Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma. Thromb Haemost 1991; 65: 3948.
  • 38
    Gurewich V, Pannell R, Broeze RJ, Mao J. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine (158). J Clin Invest 1988; 82: 195662.
  • 39
    Liu JN, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 1991; 88: 20127.
  • 40
    Braat EA, Los P, Rijken DC. The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin. Blood Coagul Fibrinolysis 1998; 9: 41927.
  • 41
    Liu JN, Gurewich V. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator. Blood 1993; 81: 9807.
  • 42
    Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombernowsky P, Dano K. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988; 111: 4251.
  • 43
    Bajzar L, Nesheim ME, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27928.
  • 44
    Valnickova Z, Enghild JJ. Human carboxypeptidase U, or thrombin-activatable fibrinolysis inhibitor, is a substrate for transglutaminases. J Biol Chem 1998; 273: 272204.
  • 45
    Francis CW, Markham RE Jr, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 22030.
  • 46
    Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1998; 86: 38591.
  • 47
    Cote HC, Bajzar L, Stevens WK, Samis JA, Morser J, MacGillivray RT, Nesheim ME. Functional characterization of recombinant human meizothrombin and meizothrombin (desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition. J Biol Chem 1997; 272: 6194200.
  • 48
    Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274: 3504652.
  • 49
    Schatteman KA, Goossens FJ, Scharpe SS, Hendriks DF. Proteolytic activation of purified human procarboxypeptidase U. Clin Chim Acta 2000; 292: 2540.
  • 50
    Lang IM, Marsh JJ, Konopka RG, Olman MA, Binder BR, Moser KM, Schleef RR. Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 1993; 87: 19902000.
  • 51
    Northeast ADR, Soo KS, Bobrow LG, Gaffney PJ, Burnand KG. The tissue-plasminogen activator and urokinase response in vivo during natural resolution of venous thrombi. J Vasc Surg 1995; 22: 5739.
  • 52
    Hashimoto M, Yamashita T, Oiwa K, Watanabe S, Giddings JC, Yamamoto J. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles. Thromb Haemost 2002; 87: 1103.
  • 53
    Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 1995; 74: 16771.
  • 54
    Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 273543.
  • 55
    Chen L, Nichols W, Mattsson C, Teger-Nilsson AC, Saldeen TG, Mehta JL. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J Pharmacol Exp Ther 1996; 277: 127683.
  • 56
    Mattsson C, Bjorkman JA, Ulvinge J-C. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis 1997; 11: 1218.
  • 57
    Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol 1993; 21: 58794.
  • 58
    Mattsson C, Bjorkman JA, Abrahamsson T, Nerme V, Schatteman K, Leurs J, Scharpe S, Hendriks D. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thromb Haemost 2002; 87: 55762.